Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

Behind the byline: Finding a ‘superstar’ to interview

KHN has never been busier - and health coverage has never been more vital. The Behind The Byline series on YouTube and Instagram TV offers an insider's view.

1 Jun 2021

New data reveals higher incidence of severe stroke in COVID-positive people

Among people who have strokes and COVID-19, there is a higher incidence of severe stroke as well as stroke in younger people, according to new data from a multinational study group on COVID-19 and stroke, led by a team of Geisinger researchers.

1 Jun 2021

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

A team of researchers from the US and Belgium applied a structure-based approach with early monitoring of cathepsin L inhibition along with SARS-CoV-2 3CLpro inhibition. They identified a potent and selective SARS-CoV-2 3CLpro inhibitor, ALG-097111, which has proven activity against SARS-CoV-2 in SARS-CoV-2 hamster models in vivo. This study is published in the journal, Biochemical and Biophysical Research Communications.

1 Jun 2021

Study offers longitudinal roadmap of immune activation and resolution in mild COVID-19

Researchers from the US recently profiled the longitudinal immune response in mild COVID-19 patients starting with early time points of 1-15 days post-infection through convalescence to over 100 days after onset of symptoms.

1 Jun 2021

Researchers identify common epitopes across SARS-CoV-2 viral variants

While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.

1 Jun 2021

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a coronavirus disease (COVID-19) treatment.

1 Jun 2021

Vitamin D may be ineffective in protecting against COVID-19

A study published in PLOS Medicine suggests that genetic evidence does not support vitamin D as a protective measure against COVID-19.

1 Jun 2021

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

Function and regeneration of dendritic cells impaired in COVID-19

A group of researchers from Germany has investigated and analyzed circulating dendritic cells and monocyte subsets in 65 hospitalized COVID-19 patients with mild to severe presentations of the infection. A variety of patients were included in their study, from those who exhibited minor signs of acute disease to convalescents, as well as healthy controls

31 May 2021

A novel multiplexed diagnostic approach for COVID-19

Researchers developed a platform for detecting the virus directly from a patient's sample as well as the immune response through antibodies such as IgG and IgM.

31 May 2021

Report on the effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in Canada

The report has recently been published on the preprint server medRxiv* by Kwong et al. (May 28th, 2021) and focused on the Pfizer-BioNTech or Moderna vaccines, confirming the supposed greater efficacy in preventing infection or severe outcomes following the administration of two doses.

31 May 2021

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

In a new research paper currently available on the bioRxiv* preprint server, a research group from the United Kingdom (UK) provides experimental evidence that B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – also known as the Indian variant of concern – shows enhanced cleavage of spike glycoprotein by furin, which can enhance its transmissibility and pathogenic traits.

31 May 2021

COVID-19 had claimed more than 3 million lives worldwide in 2020

By the end of 2020, COVID-19 had claimed the lives of more than three million people worldwide, representing 1.2 million more deaths than officially reported earlier, says a newly released report by the World Health Organization (WHO).

31 May 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

Could a mathematical application of information theory identify and predict SARS-CoV-2 mutations?

An interesting new study by researchers at the University of Portsmouth, UK, describes the use of a mathematical method to sequence genomes based on information theory. The method offers an alternative to clinical techniques, allowing mutations to be detected and possibly even predicted. In this way, it opens new research opportunities in bioinformatics and genetics.

31 May 2021

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.

31 May 2021

Inflammatory brain injury higher in men with acute COVID-19, finds study

The COVID-19 pandemic has been associated with both short- and long-term neurologic complications, including stroke, brain fog and persistent tiredness. A new study concludes that the effects of SARS-CoV-2 on the central nervous system (CNS) are due to the endothelial injury and inflammation that this produces in the brain.

31 May 2021

Pandemic News and Research

Further Reading

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

Behind the byline: Finding a ‘superstar’ to interview

New data reveals higher incidence of severe stroke in COVID-positive people

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

Study offers longitudinal roadmap of immune activation and resolution in mild COVID-19

Researchers identify common epitopes across SARS-CoV-2 viral variants

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

Vitamin D may be ineffective in protecting against COVID-19

Using Sotrovimab to treat COVID-19 early

Function and regeneration of dendritic cells impaired in COVID-19

A novel multiplexed diagnostic approach for COVID-19

Report on the effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in Canada

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

COVID-19 had claimed more than 3 million lives worldwide in 2020

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Could a mathematical application of information theory identify and predict SARS-CoV-2 mutations?

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

Inflammatory brain injury higher in men with acute COVID-19, finds study

Best practices - optimize qPCR processes for pathogen detection eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News